Meeting
2022 ASCO Annual Meeting
Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma.
Authors
Niki Gavrielatou
Department of Pathology, Yale School of Medicine, New Haven, CT
Niki Gavrielatou , Ioannis Vathiotis , Thazin Nwe Aung , Saba Shafi , Sneha Burela , Aileen Fernandez , Amanda Psyrri , David L. Rimm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6050)
DOI
10.1200/JCO.2022.40.16_suppl.6050
Abstract #
6050
Poster Bd #
42
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
Poster
2020 ASCO Virtual Scientific Program
Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study.
First Author: David Silva Moura
Poster
2018 ASCO Annual Meeting
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
First Author: Tian Zhang
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai